Cost effectiveness of multiple sclerosis drugs remains unknown
MacDonald, R.
Bmj 321(7258): 399
2000
ISSN/ISBN: 0959-8138 PMID: 10938035 Document Number: 524476
Document emailed within 1 workday
Related Documents
Richards, R.; Burls, A.; Payne, N. 2000: Cost utility of drugs for multiple sclerosis. Methods used don't calculate true benefit Bmj 320(7247): 1475; Author Reply 1475-6Fujimoto, N. 1989: A comparison of central visual field measurement by automated perimetry in optic neuritis due to multiple sclerosis and of unknown etiology Nippon Ganka Gakkai Zasshi 93(5): 581-586
Tissot, E.; Woronoff-Lemsi, M.C. 2001: Multiple sclerosis: cost of the illness Revue Neurologique (Paris) 157(8-9 Part 2): 1169-1174
Grimaud, J.; Auray, J.P.; Collectif-Sep-Des-Villes-Et-Sep-Des-Champs 2004: Quality of life and economic cost of multiple sclerosis Revue Neurologique (Paris) 160(1): 23-34
Kolasa, K. 2013: How much is the cost of multiple sclerosis--systematic literature review Przeglad Epidemiologiczny 67(1): 75-9 157-60
Millar, J.A. 2019: The cost of teriflunomide in the treatment of relapsing-remitting multiple sclerosis New Zealand Medical Journal 132(1490): 36-41
Walusiak, J. 2000: Baker's asthma: what remains still unknown about it? Medycyna Pracy 51(1): 45-50
Pollock, K.; Grime, J. 2000: Patients' views on cost effectiveness of drugs are important Bmj 321(7271): 1292
Mehta, J.; Duff, S.B.; Gupta, S. 2004: Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma Managed Care Interface 17(9): 52-61
Lopert, R.; Lang, D.L.; Hill, S.R.; Henry, D.A. 2002: Differential pricing of drugs: a role for cost-effectiveness analysis? Lancet 359(9323): 2105-2107
Splett, P.L. 1991: Phase I: status report of existing data on the effectiveness, cost, and cost effectiveness of nutrition care services Journal of the American Dietetic Association Suppl: S9-14
Splett, P.L. 1991: Phase I: status report of existing data on the effectiveness, cost, and cost effectiveness of nutrition care services Journal of the American Dietetic Association Suppl: S9-14
Svenningsson, A.; Andersson, M.; Olsson, T. 1998: Treatment of multiple sclerosis--1. New drugs may be effective but there still are frequent relapses Lakartidningen 95(49): 5623-7 5630
Rubio-Terrés, C.; Domínguez-Gil Hurlé, A. 2005: Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain Revista de Neurologia 40(12): 705-710
Messori, A.; Trippoli, S.; Vaiani, M. 2002: Efficacy, safety, and cost of new anticancer drugs. Price needs to be evaluated against effectiveness Bmj 325(7375): 1302; Author Reply 1302
Hawkes, N. 2014: NICE uses wrong comparator to assess cost effectiveness of new drugs, report says Bmj 348: G2134
Schanke, A.K.; Grimsmo, J.; Sundet, K. 1995: Multiple sclerosis and prerequisites for driver's licence. A retrospective study of 33 patients with multiple sclerosis assessed at Sunnaas hospital Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 115(11): 1349-1352
Bykova, O.V.; Nankina, I.A.; Platonova, A.N.; Karpacheva, N.G.; Petrova, O.A.; Gorina, T.P.; Batysheva, T.T.; Serkov, S.V.; Kuzenkova, L.M. 2013: Differential diagnosis of multiple sclerosis with pediatric onset: the experience of the Moscow Division for treatment of children and adolescents with multiple sclerosis Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 113(10 Pt 2): 61-68
Laosanguanek, N.; Wiroteurairuang, T.; Siritho, S.; Prayoonwiwat, N. 2011: Reliability of the Thai version of SF-36 questionnaire for an evaluation of quality of life in multiple sclerosis patients in multiple sclerosis clinic at Siriraj Hospital Journal of the Medical Association of Thailand 94 Suppl. 1: S84-S88
Boelaert, M.; Le Ray, D.; Van Der Stuyft, P. 2002: How better drugs could change kala-azar control. Lessons from a cost-effectiveness analysis Tropical Medicine and International Health: Tm and Ih 7(11): 955-959